• About us
• Contact

Advertisement

Organisation › Details

Numab (Group)

Numab Therapeutics AG is a clinical-stage company developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms ?-CapTM and MATCHTM puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of new and important medicines aimed to maximize patient benefits. Numab’s diverse research pipeline spans multiple therapeutic areas and creates the opportunity for the next generation of first-in-class and best-in-class medicines. Our lead asset, NM32, a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies, is currently in Phase 1 trial in patients with solid tumors. Numab’s partnerships with multiple leading pharma companies continue to validate the robust proprietary platform and development capabilities. *

 

	Start	2011-06-01 established
	Industry	antibody technology
	Industry 2	therapeutic antibody
	Person	Urech, David (Numab 201910 CEO + Co-Founder before Esbatech 2004–2010)
	Person 2	Middendorp, Oliver (Numab 201703 CBO + Co-Founder before Esbatech 2004–2010)
	Region	Horgen ZH
	Country	Switzerland
	Street	5 Bachtobelstr.
	City	8810 Horgen ZH
		Address record changed: 2025-01-12
Basic data	Employees	n. a.
		* Document for »About Section«: Numab Therapeutics AG. (1/9/25). "Press Release: Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing". Horgen.
		Record changed: 2025-03-16

Advertisement

More documents for Numab (Group)

• [1] Numab Therapeutics AG. (1/9/25). "Press Release: Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing". Horgen....
• [2] Numab Therapeutics AG. (5/28/24). "Press Release: Numab Therapeutics Announces Johnson & Johnson to Acquire Its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis". H...
• [3] Numab Therapeutics AG. (5/20/21). "Press Release: Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing". Wädenswil (Zurich)....
• [4] Numab Therapeutics AG. (1/13/21). "Press Release: Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option". Wädenswil (Zurich)....
• [5] Numab Therapeutics AG. (9/30/20). "Press Release: Numab Therapeutics Appoints Daniel Vasella as New Chairman of the Board". Wädenswil (Zurich)....
• [6] Numab Therapeutics AG. (7/7/20). "Press Release: Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases". Wädenswil & Ingelheim....
• [7] Numab Therapeutics AG. (3/30/20). "Press Release: Numab Therapeutics Expands Immuno-Oncology Research Alliance with Ono Pharmaceutical Co., Ltd.". Wädenswil (Zurich)....
• [8] Numab Therapeutics AG. (3/9/20). "Press Release: Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology". Wädenswil (Zurich)....
• [9] Numab Therapeutics AG. (12/12/19). "Press Release: Numab Therapeutics and 3SBio’s Subsidiary Sunshine Guojian Form Partnership to Develop a Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology". Wädenswil, Shengyang & Shanghai....
• [10] Numab Therapeutics AG. (10/15/19). "Press Release: Numab Appoints Daniel Vasella to Board of Directors". Wädenswil (Zurich)....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.